BioNTech SE research snapshot
BNTX AI stock analysis reads BioNTech SE as a well-capitalized oncology and immunotherapy developer still transitioning away from COVID-19 vaccine dependence. At the August 2, 2026 data cutoff, BNTX last closed near $90.58 on July 31, with an implied market capitalization of about $22.91 billion. A large cash and securities balance funds late-stage oncology programs, and management is cutting costs and repurchasing stock, but the company still posts losses and faces binary clinical readouts, a scheduled Q2 2026 report on August 4, and a co-founder leadership transition. This is informational research, not investment advice.
Current price
$90.58
Market cap
$22.91 billion
AI score
61 / 100
Rating
Cash-backed oncology transition with high clinical and leadership risk
Trend status
Below the 50-day and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BioNTech sells COVID-19 vaccines and builds oncology medicines, immunomodulators, and antibody-drug conjugates that must prove clinical benefit and commercial adoption. | Medium |
| Moat | mRNA expertise, oncology research, manufacturing, regulatory experience, intellectual property, and partnerships create barriers, but large pharma and other biotech firms compete for the same targets. | Medium |
| Management | The founders built the mRNA platform and COVID franchise, but their planned move to a new independent company by the end of 2026 makes successor quality and capital-allocation discipline central risks. | Medium |
| Financial trend | FY2025 revenue was €2.870 billion and net loss was €1.136 billion. Q1 2026 revenue was €118.1 million and net loss was €531.9 million, reflecting seasonal COVID demand and continued oncology investment. | High |
| Valuation | At $90.58, BNTX traded near 1.06x book value and 31.38x trailing free cash flow, with a price-to-sales ratio near 7.08x. P/E is not meaningful because trailing EPS is negative. | Medium |
| Technical trend | The July 31 snapshot placed price below both the 50-day and 200-day moving averages with neutral momentum, which supports a neutral to cautious technical view. | Medium |
| Risk level | Risk is high because late-stage oncology studies, spending, COVID demand, competition, regulatory decisions, integration, the new buyback, and executive succession can all move the equity sharply. | High |
| AI confidence | Reported facts are well supported, but any forecast has limited confidence because clinical evidence and strategic decisions can outweigh historical financial trends. | Medium |
| Investment certainty | Cash runway and a buyback do not equal a proven earnings stream. Investment certainty remains below data confidence until oncology programs produce repeatable commercial evidence. | Low-medium |
BNTX AI stock forecast
The BNTX AI stock forecast uses scenario ranges rather than a precise price prediction. Trailing EPS is negative, so a standard EPS times P/E target is not suitable. The practical range instead reflects net cash coverage, oncology data, COVID revenue, cost execution, the new buyback, and the market value assigned to the pipeline. Analyst consensus as of the cutoff was Buy with an average target near $122.59 and a spread from about $76.13 to $154.92.
$125 to $150
More likely if pumitamig global data stay encouraging across ROSETTA trials, gotistobart interim results are positive, ADC programs such as trastuzumab pamirtecan clear BLA milestones, the BMS collaboration advances, and cost savings plus the share buyback support sentiment.
$85 to $110
More likely if 2026 revenue follows the €2.0 billion to €2.3 billion guide, the cash balance remains strong, data are mixed but adequate, and the market waits for clearer approval and launch evidence after the August 4 Q2 report.
$62 to $80
More likely if pivotal studies disappoint, COVID revenue falls faster than expected, site consolidation or integration costs exceed plans, the leadership transition creates execution concerns, or the market discounts the pipeline more heavily.
BNTX AI technical analysis
BNTX AI technical analysis is neutral to cautious as of the August 2, 2026 cutoff. StockAnalysis showed a July 31 close of $90.58, a 50-day moving average of $91.34, a 200-day moving average of $98.22, and RSI of 45.77. Price was below both moving averages, so a durable uptrend still needs confirmation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $90.58 | July 31, 2026 closing quote used for market-cap math and technical context. |
| Near support | $88 to $90 | The July 31 day range bottomed near $90.45, and the 50-day moving average near $91.34 sits just above price as the nearest trend reference. |
| Secondary support | $79.52 | The 52-week low area near $79.52 is the next visible support zone from the chart snapshot. |
| Resistance | $91 to $92 | The 50-day moving average near $91.34 is the first meaningful recovery hurdle. |
| Higher resistance | $98 to $99 | The 200-day moving average near $98.22 marks the longer-term resistance zone. |
| 52-week high | $124.00 | The chart snapshot listed a 52-week high of $124.00, a larger upside reference if price reclaims the moving averages. |
| Momentum | RSI 45.77, neutral | Momentum was neither oversold nor overbought, so clinical news, the August 4 earnings print, and volume confirmation matter more than RSI alone. |
| Volume | About 0.77 million 20-day average shares | A breakout should be judged against average volume because oncology, regulatory, and earnings news can create short-lived spikes. |
| Volatility | Elevated event-driven biotech volatility | Beta was about 1.32, and clinical readouts, regulatory updates, earnings, cost-cutting plans, and executive news can override chart levels. |
| Invalidation | Close below $88, then $79.52 | A sustained break below the recent reaction zone weakens the range setup. A break below the 52-week-low area would require a full thesis review. |
BNTX AI trading strategy
The BNTX AI trading strategy is a rules-based research framework for an event-driven biotechnology stock. It is not personal advice and should be used with live prices, position sizing, filings, trial calendars, and independent risk limits.
Watch for BNTX to hold the $88 to $90 support area and reclaim the 50-day and then 200-day moving averages near $91 and $98 with above-average volume and no adverse clinical, earnings, or management news.
A sustained close below the recent support should reduce confidence. A break below $79.52 should invalidate the range thesis and prompt a fresh fundamental review.
If BNTX revisits support without new adverse data, compare the price move with cash preservation, 2026 revenue guidance, the August 4 Q2 report, trial milestones, and the probability of oncology commercialization.
Do not treat a clinical, earnings, or leadership-driven selloff as ordinary technical noise. Define a loss limit before entry because news gaps can be large.
Track quarterly revenue, cash and securities, R&D and SG&A guidance, the €500 million annual cost savings plan from site consolidation, the up to $1 billion ADS repurchase program, BMS collaboration progress, pumitamig and gotistobart studies, ADC milestones, COVID demand, and management succession.
Reduce confidence if cash declines without stronger clinical or commercial evidence, if cost savings or buyback execution fall short, or if pivotal timelines repeatedly slip.
Investment research summary
BioNTech converts mRNA, immuno-oncology, antibody-drug conjugate, clinical-development, and manufacturing capabilities into medicines that need measurable patient benefit, regulatory approval, reimbursement, and reliable delivery.
The moat is a combination of mRNA expertise, cancer research, intellectual property, manufacturing, regulatory know-how, data, and partnerships. It is not permanent: better clinical profiles, faster execution, or stronger commercial infrastructure from competitors can narrow it.
The thesis fails if oncology data do not translate into approvals, the acquired and partnered programs do not justify their cost, COVID revenue erodes faster than spending, site consolidation disrupts supply or morale, leadership transition interrupts execution, or the cash balance is spent before a durable product base arrives.
Management built a globally important mRNA company, launched a buyback, and is consolidating manufacturing to cut about €500 million in annual costs by 2029. The planned move of co-founders Ugur Sahin and Özlem Türeci to a new independent company by the end of 2026 creates key-person and succession risk. The next team must allocate capital carefully and execute launches.
Cancer immunotherapy and precision medicines remain long-term growth areas. BioNTech sits in a competitive field where large trials, combination science, safety, reimbursement, and sales execution determine whether a promising platform becomes a durable commercial business.
The balance sheet provides a meaningful cushion, but it is not a complete margin of safety because the market must fund years of development before commercial success is proven. Negative EPS makes a normal P/E valuation unreliable; the key question is the value created per unit of cash consumed, with net cash per share near $61.11 supporting part of the price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BNTX price | $90.58 at the July 31, 2026 close | StockAnalysis quote snapshot | August 2, 2026 |
| Market capitalization | $22.91 billion, verified as $90.58 x 252.884261 million shares | financial_rigor.py, BioNTech Q1 2026 release, and StockAnalysis | August 2, 2026 |
| FY2025 revenue | €2.870 billion | BioNTech FY2025 results and StockAnalysis cross-check | August 2, 2026 |
| FY2025 net loss | €1.136 billion | BioNTech FY2025 results and StockAnalysis cross-check | August 2, 2026 |
| Q1 2026 revenue and net loss | €118.1 million revenue and €531.9 million net loss | BioNTech Q1 2026 financial results | August 2, 2026 |
| Cash, cash equivalents, and security investments | €16.763 billion at March 31, 2026; net cash near $61.11 per share | BioNTech Q1 2026 financial results and StockAnalysis | August 2, 2026 |
| 2026 revenue guidance | €2.0 billion to €2.3 billion | BioNTech Q1 2026 financial results | August 2, 2026 |
| Q2 2026 results date | August 4, 2026, before market open | StockAnalysis earnings calendar and BioNTech announcement | August 2, 2026 |
| Analyst consensus and price targets | Buy consensus with an average target of $122.59 and a range of $76.13 to $154.92 across 20 analysts | StockAnalysis forecast page (S&P Global and TipRanks data) | August 2, 2026 |
| Valuation math | P/E not meaningful with negative EPS; P/B about 1.06x, P/FCF about 31.38x, P/S about 7.08x, EV/Sales about 2.30x | financial_rigor.py using StockAnalysis per-share inputs | August 2, 2026 |
| Moving averages and momentum | 50-day $91.34, 200-day $98.22, RSI 45.77 | StockAnalysis technical snapshot | August 2, 2026 |
| Cost savings and buyback plans | Up to about €500 million in annual savings by 2029 from site consolidation; new ADS repurchase program of up to $1.0 billion over 12 months | BioNTech Q1 2026 financial results | August 2, 2026 |
This BNTX AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on public filings, quote snapshots, technical data, analyst consensus, and third-party sources available as of August 2, 2026. They may be wrong, incomplete, or outdated after earnings, trial data, regulatory decisions, leadership changes, cash-burn updates, buyback execution, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
